AustralieFrV1, PascalFrancis, Curation, bibRecord, 005B53

Mass treatment to eliminate tuberculosis from an island population

Identifieur interne : 005B53 ( PascalFrancis/Curation ); précédent : 005B52; suivant : 005B54

Mass treatment to eliminate tuberculosis from an island population

Auteurs : P. C. Hill [Nouvelle-Zélande] ; C. Dye [Suisse] ; K. Viney ; K. Tabutoa [Suisse, Kiribati] ; T. Kienene [Kiribati] ; K. Bissell [France, Nouvelle-Zélande] ; B. G. Williams [Afrique du Sud] ; R. Zachariah [Belgique] ; B. J. Marais [Australie] ; A. D. Harries [France, Royaume-Uni]

Source :

The International journal of tuberculosis and lung disease [ 1027-3719 ] ; 2014.

RBID : Pascal:14-0196387

Descripteurs français

Pascal (Inist)
- Tuberculose, Pathologie de l'appareil respiratoire, Campagne de masse, Traitement, Ile, Homme, Population, Elimination.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Elimination, Human, Island, Mass campaign, Population, Respiratory disease, Treatment, Tuberculosis.

Abstract

SETTING: The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence. OBJECTIVE: To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati. METHODS: We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. RESULTS: Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of ≥90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. CONCLUSION: Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.

A01	`01`	`1`		`@0 1027-3719`
A03		`1`		`@0 Int. j. tuberc. lung dis.`
A05				`@2 18`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Mass treatment to eliminate tuberculosis from an island population`
A11	`01`	`1`		`@1 HILL (P. C.)`
A11	`02`	`1`		`@1 DYE (C.)`
A11	`03`	`1`		`@1 VINEY (K.)`
A11	`04`	`1`		`@1 TABUTOA (K.)`
A11	`05`	`1`		`@1 KIENENE (T.)`
A11	`06`	`1`		`@1 BISSELL (K.)`
A11	`07`	`1`		`@1 WILLIAMS (B. G.)`
A11	`08`	`1`		`@1 ZACHARIAH (R.)`
A11	`09`	`1`		`@1 MARAIS (B. J.)`
A11	`10`	`1`		`@1 HARRIES (A. D.)`
A14	`01`			`@1 Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago @2 Dunedin @3 NZL @Z 1 aut.`
A14	`02`			`@1 HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization @2 Geneva @3 CHE @Z 2 aut. @Z 4 aut.`
A14	`03`			`@1 Public Health Division, Secretariat of the Pacific Community @2 Noumea @3 NCL @Z 3 aut.`
A14	`04`			`@1 National Tuberculosis Control Programme, Ministry of Health and Medical Services @3 KIR @Z 4 aut. @Z 5 aut.`
A14	`05`			`@1 International Union Against Tuberculosis and Lung Disease @2 Paris @3 FRA @Z 6 aut. @Z 10 aut.`
A14	`06`			`@1 School of Population Health, University of Auckland @2 Auckland @3 NZL @Z 6 aut.`
A14	`07`			`@1 South African Centre for Epidemiological Modelling and Analysis @2 Cape Town @3 ZAF @Z 7 aut.`
A14	`08`			`@1 Médecins Sans Frontières, Brussels Operational Centre @2 Luxembourg @3 BEL @Z 8 aut.`
A14	`09`			`@1 Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney @2 Sydney, New South Wales @3 AUS @Z 9 aut.`
A14	`10`			`@1 London School of Hygiene & Tropical Medicine @2 London @3 GBR @Z 10 aut.`
A20				`@1 899-904`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26450 @5 354000504815800050`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 14-0196387`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The International journal of tuberculosis and lung disease`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 SETTING: The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence. OBJECTIVE: To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati. METHODS: We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. RESULTS: Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of ≥90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. CONCLUSION: Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.
C02	`01`	`X`		`@0 002B11`
C02	`02`	`X`		`@0 002B05B02O`
C03	`01`	`X`	`FRE`	`@0 Tuberculose @5 01`
C03	`01`	`X`	`ENG`	`@0 Tuberculosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Tuberculosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 02`
C03	`02`	`X`	`ENG`	`@0 Respiratory disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Campagne de masse @5 09`
C03	`03`	`X`	`ENG`	`@0 Mass campaign @5 09`
C03	`03`	`X`	`SPA`	`@0 Campaña de población @5 09`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 10`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 10`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 10`
C03	`05`	`X`	`FRE`	`@0 Ile @5 11`
C03	`05`	`X`	`ENG`	`@0 Island @5 11`
C03	`05`	`X`	`SPA`	`@0 Isla @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Population @5 13`
C03	`07`	`X`	`ENG`	`@0 Population @5 13`
C03	`07`	`X`	`SPA`	`@0 Población @5 13`
C03	`08`	`X`	`FRE`	`@0 Elimination @5 14`
C03	`08`	`X`	`ENG`	`@0 Elimination @5 14`
C03	`08`	`X`	`SPA`	`@0 Eliminación @5 14`
C07	`01`	`X`	`FRE`	`@0 Mycobactériose`
C07	`01`	`X`	`ENG`	`@0 Mycobacterial infection`
C07	`01`	`X`	`SPA`	`@0 Micobacteriosis`
C07	`02`	`X`	`FRE`	`@0 Bactériose`
C07	`02`	`X`	`ENG`	`@0 Bacteriosis`
C07	`02`	`X`	`SPA`	`@0 Bacteriosis`
C07	`03`	`X`	`FRE`	`@0 Infection`
C07	`03`	`X`	`ENG`	`@0 Infection`
C07	`03`	`X`	`SPA`	`@0 Infección`
N21				`@1 244`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000309

Links to Exploration step

Pascal:14-0196387

Curation

No country items

K. Viney

<affiliation><inist:fA14 i1="03"><s1>Public Health Division, Secretariat of the Pacific Community</s1>
<s2>Noumea</s2>
<s3>NCL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>NCL</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mass treatment to eliminate tuberculosis from an island population</title>
<author><name sortKey="Hill, P C" sort="Hill, P C" uniqKey="Hill P" first="P. C." last="Hill">P. C. Hill</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago</s1>
<s2>Dunedin</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Dye, C" sort="Dye, C" uniqKey="Dye C" first="C." last="Dye">C. Dye</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Viney, K" sort="Viney, K" uniqKey="Viney K" first="K." last="Viney">K. Viney</name>
<affiliation><inist:fA14 i1="03"><s1>Public Health Division, Secretariat of the Pacific Community</s1>
<s2>Noumea</s2>
<s3>NCL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>NCL</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabutoa, K" sort="Tabutoa, K" uniqKey="Tabutoa K" first="K." last="Tabutoa">K. Tabutoa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Tuberculosis Control Programme, Ministry of Health and Medical Services</s1>
<s3>KIR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Kiribati</country>
</affiliation>
</author>
<author><name sortKey="Kienene, T" sort="Kienene, T" uniqKey="Kienene T" first="T." last="Kienene">T. Kienene</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Tuberculosis Control Programme, Ministry of Health and Medical Services</s1>
<s3>KIR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Kiribati</country>
</affiliation>
</author>
<author><name sortKey="Bissell, K" sort="Bissell, K" uniqKey="Bissell K" first="K." last="Bissell">K. Bissell</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Union Against Tuberculosis and Lung Disease</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>School of Population Health, University of Auckland</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Williams, B G" sort="Williams, B G" uniqKey="Williams B" first="B. G." last="Williams">B. G. Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>South African Centre for Epidemiological Modelling and Analysis</s1>
<s2>Cape Town</s2>
<s3>ZAF</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
</affiliation>
</author>
<author><name sortKey="Zachariah, R" sort="Zachariah, R" uniqKey="Zachariah R" first="R." last="Zachariah">R. Zachariah</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Médecins Sans Frontières, Brussels Operational Centre</s1>
<s2>Luxembourg</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Marais, B J" sort="Marais, B J" uniqKey="Marais B" first="B. J." last="Marais">B. J. Marais</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Harries, A D" sort="Harries, A D" uniqKey="Harries A" first="A. D." last="Harries">A. D. Harries</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Union Against Tuberculosis and Lung Disease</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>London School of Hygiene & Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0196387</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0196387 INIST</idno>
<idno type="RBID">Pascal:14-0196387</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000309</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005B53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mass treatment to eliminate tuberculosis from an island population</title>
<author><name sortKey="Hill, P C" sort="Hill, P C" uniqKey="Hill P" first="P. C." last="Hill">P. C. Hill</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago</s1>
<s2>Dunedin</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Dye, C" sort="Dye, C" uniqKey="Dye C" first="C." last="Dye">C. Dye</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
</author>
<author><name sortKey="Viney, K" sort="Viney, K" uniqKey="Viney K" first="K." last="Viney">K. Viney</name>
<affiliation><inist:fA14 i1="03"><s1>Public Health Division, Secretariat of the Pacific Community</s1>
<s2>Noumea</s2>
<s3>NCL</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<wicri:noCountry>NCL</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabutoa, K" sort="Tabutoa, K" uniqKey="Tabutoa K" first="K." last="Tabutoa">K. Tabutoa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Suisse</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Tuberculosis Control Programme, Ministry of Health and Medical Services</s1>
<s3>KIR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Kiribati</country>
</affiliation>
</author>
<author><name sortKey="Kienene, T" sort="Kienene, T" uniqKey="Kienene T" first="T." last="Kienene">T. Kienene</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Tuberculosis Control Programme, Ministry of Health and Medical Services</s1>
<s3>KIR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Kiribati</country>
</affiliation>
</author>
<author><name sortKey="Bissell, K" sort="Bissell, K" uniqKey="Bissell K" first="K." last="Bissell">K. Bissell</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Union Against Tuberculosis and Lung Disease</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>School of Population Health, University of Auckland</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author><name sortKey="Williams, B G" sort="Williams, B G" uniqKey="Williams B" first="B. G." last="Williams">B. G. Williams</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>South African Centre for Epidemiological Modelling and Analysis</s1>
<s2>Cape Town</s2>
<s3>ZAF</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
</affiliation>
</author>
<author><name sortKey="Zachariah, R" sort="Zachariah, R" uniqKey="Zachariah R" first="R." last="Zachariah">R. Zachariah</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Médecins Sans Frontières, Brussels Operational Centre</s1>
<s2>Luxembourg</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
</affiliation>
</author>
<author><name sortKey="Marais, B J" sort="Marais, B J" uniqKey="Marais B" first="B. J." last="Marais">B. J. Marais</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Harries, A D" sort="Harries, A D" uniqKey="Harries A" first="A. D." last="Harries">A. D. Harries</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>International Union Against Tuberculosis and Lung Disease</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>London School of Hygiene & Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The International journal of tuberculosis and lung disease</title>
<title level="j" type="abbreviated">Int. j. tuberc. lung dis.</title>
<idno type="ISSN">1027-3719</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The International journal of tuberculosis and lung disease</title>
<title level="j" type="abbreviated">Int. j. tuberc. lung dis.</title>
<idno type="ISSN">1027-3719</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Elimination</term>
<term>Human</term>
<term>Island</term>
<term>Mass campaign</term>
<term>Population</term>
<term>Respiratory disease</term>
<term>Treatment</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tuberculose</term>
<term>Pathologie de l'appareil respiratoire</term>
<term>Campagne de masse</term>
<term>Traitement</term>
<term>Ile</term>
<term>Homme</term>
<term>Population</term>
<term>Elimination</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">SETTING: The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence. OBJECTIVE: To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati. METHODS: We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. RESULTS: Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of ≥90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. CONCLUSION: Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1027-3719</s0>
</fA01>
<fA03 i2="1"><s0>Int. j. tuberc. lung dis.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Mass treatment to eliminate tuberculosis from an island population</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HILL (P. C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DYE (C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VINEY (K.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TABUTOA (K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KIENENE (T.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BISSELL (K.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WILLIAMS (B. G.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ZACHARIAH (R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MARAIS (B. J.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>HARRIES (A. D.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago</s1>
<s2>Dunedin</s2>
<s3>NZL</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Public Health Division, Secretariat of the Pacific Community</s1>
<s2>Noumea</s2>
<s3>NCL</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>National Tuberculosis Control Programme, Ministry of Health and Medical Services</s1>
<s3>KIR</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>International Union Against Tuberculosis and Lung Disease</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>School of Population Health, University of Auckland</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>South African Centre for Epidemiological Modelling and Analysis</s1>
<s2>Cape Town</s2>
<s3>ZAF</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Médecins Sans Frontières, Brussels Operational Centre</s1>
<s2>Luxembourg</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney</s1>
<s2>Sydney, New South Wales</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>London School of Hygiene & Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>899-904</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26450</s2>
<s5>354000504815800050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0196387</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The International journal of tuberculosis and lung disease</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>SETTING: The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence. OBJECTIVE: To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati. METHODS: We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis. RESULTS: Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of ≥90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB. CONCLUSION: Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B11</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05B02O</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tuberculose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Tuberculosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tuberculosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Campagne de masse</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mass campaign</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Campaña de población</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ile</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Island</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Isla</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Population</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Population</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Población</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Elimination</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Elimination</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Eliminación</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Mycobactériose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mycobacterial infection</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Micobacteriosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>244</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B53 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005B53 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0196387
   |texte=   Mass treatment to eliminate tuberculosis from an island population
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Mass treatment to eliminate tuberculosis from an island population

Mass treatment to eliminate tuberculosis from an island population

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri